E2F8 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the E2F8 gene in the near-haploid HAP1 human cell line. This genetically engineered model provides a powerful tool for studying the loss of function of E2F8, an atypical E2F family transcription factor that acts as a key repressor of cell cycle progression and angiogenesis. The polyclonal nature preserves genetic diversity while ensuring effective gene disruption, enabling robust functional investigations in a simplified genomic context.
HAP1 cells derive from the KBM-7 chronic myeloid leukemia cell line and possess a near-haploid karyotype, with only one copy of most chromosomes. This unique feature eliminates the complication of heterozygous alleles, allowing unambiguous interpretation of gene knockout phenotypes. HAP1 cells maintain intact components of the p53 and E2F signaling networks, making them a physiologically relevant platform for dissecting mechanisms of cell cycle control, tumor suppression, and angiogenic regulation in a hematopoietic lineage setting.
E2F8 operates as a transcriptional repressor within the E2F regulatory network, forming complexes with DP family proteins and interacting with other E2F members and RB1. Its activity is modulated by upstream factors including E2F1, E2F2, E2F3, TP53, and cyclin-dependent kinases, and it directly represses transcription of critical E2F target genes such as CCNA2 (cyclin A2), CCNB1 (cyclin B1), and CDK1. By silencing these genes, E2F8 inhibits cell cycle entry and endothelial cell functions, thereby suppressing both proliferation and angiogenesis. Disruption of E2F8 relieves this repression, leading to upregulation of its targets and promotion of these biological processes.
In the HAP1 background, E2F8 knockout provides a clean genetic model in which the repressive functions of this transcription factor can be dissected without interference from diploid gene redundancy. The near-haploid state enhances the penetrance of resulting phenotypes, facilitating the study of deregulated cell cycle progression, altered DNA damage responses, and abnormal angiogenic signaling. Because HAP1 cells are easily amenable to high-throughput genetic and chemical screens, this model enables systematic interrogation of E2F8-dependent pathways and identification of synthetic lethal interactions or therapeutic vulnerabilities in cancer.
This knockout product is ideal for a range of experimental applications, including quantitative cell cycle analysis via flow cytometry, proliferation and apoptosis assays, and functional angiogenesis studies using migration and tube formation assays. Researchers can validate target gene derepression and pathway alterations using western blotting, RT-qPCR, and ChIP-qPCR, enabling detailed molecular characterization. The model supports investigations into leukemia, solid tumors, and angiogenesis-related disorders, providing a versatile tool for both fundamental and translational research. For additional product details or technical support, please contact Ascent Research.
